SHOW / EPISODE

Moderna (MRNA): Why Software Is Now Part of the Cancer Drug [Q3 2026]

10m | Nov 6, 2026

Moderna (MRNA) wired out a $950M patent settlement in Q3 2026 yet still expanded its cash pile to $8B while locking proprietary software into its first cancer drug filing. 🧬


In ~10 minutes:

- Why $1.37B in uncollected vaccine IOUs masked Q3 operating cash burn

- Raising $2.6B in 0% convertible debt to fund the oncology pivot

- How proprietary antigen-selection software becomes part of the melanoma BLA

- Abruptly halting the second norovirus trial cohort to trim $200M in R&D

- Missing the spring pharmacy contracting window for the new flu shot


While multi-year international government vaccine contracts drove a 29% YoY revenue beat and a full-year guidance hike, the real story is Moderna's transition into a personalized oncology powerhouse. We unpack the bioinformatics breakthrough that allowed Moderna to scale its neoantigen training dataset from just 7 willing patients in Phase 2 to standard whole-blood draws in Phase 3.


Company: Moderna, Inc. (MRNA) | Q3 FY2026

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.

Paused
Audio Player Image
Earnings Unscripted: Stock Earnings Calls & Analysis
Loading...